Maxims latest update....
http://www.immutep.com/investors-me...partners-are-busy-novartis-gsk-eoc-china.html
Of interest Maxim's suggest GSK is moving into PH2 with IMP731 whereas as
the very recent operational update by immutep states it was simply building
on current PH1 in a different direction.....
I think I'm reading that correctly.......
If Maxims is correct, that means we will be associated with 5 ph2 trials
by years end with tacti-Mel possibly not too far behind......Not bad in
4 years....
Ann: TACTI-mel Patient Recruitment Complete & Operational Update, page-16
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16280 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 4940 | 1 |
View Market Depth
| Last trade - 10.00am 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable
